Mitchell Weisberg
Vernon Hills, ILNPI 1578555306
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $24,000 of the $30,558 with a category attached, or 78.5%. AbbVie accounts for 86.7% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2022 at $9,248 and has fallen 99.8% since, to $19 in 2024.
Across 299 payments — averaging $102.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$26K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$469
- Otsuka America Pharmaceutical, Inc.$339
- Novo Nordisk$314
- Lundbeck LLC$249
- Neurocrine Biosciences, Inc.$244
- plus $2K from 31 others
What the payments were for
- Speaking & faculty fees$24,00079%
- Travel & lodging$1,0343%
- Food & beverage$5,46518%
- Education$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 108 | $26,493 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 21 | $469 |
| Otsuka America Pharmaceutical, Inc. | 21 | $339 |
| Novo Nordisk | 4 | $314 |
| Lundbeck LLC | 16 | $249 |
| Neurocrine Biosciences, Inc. | 11 | $244 |
| Johnson & Johnson | 10 | $237 |
| Supernus Pharmaceuticals, Inc. | 10 | $228 |
| Alkermes, Inc. | 9 | $184 |
| Teva Pharmaceuticals USA, Inc. | 7 | $146 |
| Lilly USA, LLC | 3 | $145 |
| Pfizer | 6 | $126 |
| Neos Therapeutics, LP | 7 | $124 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $113 |
| Tris Pharma Inc | 5 | $107 |
| Axsome Therapeutics, Inc. | 4 | $91 |
| Shire North American Group Inc | 5 | $84 |
| Avanir Pharmaceuticals, Inc. | 5 | $78 |
| Biogen | 4 | $73 |
| Almatica Pharma LLC | 4 | $72 |
| Ironshore Pharmaceuticals Inc. | 4 | $66 |
| Idorsia Pharmaceuticals US Inc | 3 | $65 |
| Jazz Pharmaceuticals Inc. | 3 | $62 |
| Bausch Health US, LLC | 3 | $56 |
| Harmony Biosciences LLC | 3 | $55 |
| Corium, LLC | 2 | $48 |
| Acadia Pharmaceuticals Inc | 2 | $39 |
| Vertical Pharmaceuticals, LLC | 2 | $38 |
| Azurity Pharmaceuticals, Inc. | 2 | $37 |
| Adlon Therapeutics L.p. | 2 | $34 |
| Collegium Pharmaceutical, Inc. | 1 | $24 |
| USWM, LLC | 1 | $23 |
| Eisai Inc. | 1 | $22 |
| Indivior Inc. | 1 | $20 |
| Livanova USA, Inc. | 1 | $20 |
| Alfasigma USA, Inc. | 1 | $18 |
| Amgen | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.